Contemporary Artificial Pancreas (AP) consists of a subcutaneous (SC) glucose sensor, a SC insulin pump and a control algorithm. Even the most advanced systems are far from optimal, in particular due to the non-physiologic nature of SC route. While SC insulin delivery is convenient and minimally invasive, it introduces delays to insulin action that make tight control difficult, particularly during meals. In addition frequent patient interventions are needed, e.g., at mealtime. The intraperitoneal (IP) insulin delivery could address this major challenge since it exhibits a faster pharmacokinetics/pharmacodynamics, hence making easier to quickly respond to glycemic disturbances. A 1-day hospital closed-loop study has shown significant improvements of IP glucose control vs SC AP, and that meal announcement is not necessary. However, the IP AP has not been tested in more realistic everyday life conditions. In this work we have performed an in silico study of 14 days of an IP AP by using the UVA/Padova simulator which includes intra- and inter-day variability of insulin sensitivity and several real life scenarios. We show superiority of IP AP vs SC AP in terms of quality of glucose control (time in range 87% IP vs 80% SC) without the need of a meal announcement.

Artificial Pancreas: In Silico Study Shows No Need of Meal Announcement and Improved Time in Range of Glucose with Intraperitoneal vs. Subcutaneous Insulin Delivery

Toffanin C.;Magni L.;Cobelli C.
2021

Abstract

Contemporary Artificial Pancreas (AP) consists of a subcutaneous (SC) glucose sensor, a SC insulin pump and a control algorithm. Even the most advanced systems are far from optimal, in particular due to the non-physiologic nature of SC route. While SC insulin delivery is convenient and minimally invasive, it introduces delays to insulin action that make tight control difficult, particularly during meals. In addition frequent patient interventions are needed, e.g., at mealtime. The intraperitoneal (IP) insulin delivery could address this major challenge since it exhibits a faster pharmacokinetics/pharmacodynamics, hence making easier to quickly respond to glycemic disturbances. A 1-day hospital closed-loop study has shown significant improvements of IP glucose control vs SC AP, and that meal announcement is not necessary. However, the IP AP has not been tested in more realistic everyday life conditions. In this work we have performed an in silico study of 14 days of an IP AP by using the UVA/Padova simulator which includes intra- and inter-day variability of insulin sensitivity and several real life scenarios. We show superiority of IP AP vs SC AP in terms of quality of glucose control (time in range 87% IP vs 80% SC) without the need of a meal announcement.
File in questo prodotto:
File Dimensione Formato  
IEEE_Toffanin_Magni_Cobelli.pdf

accesso aperto

Descrizione: © 2021 IEEE Personal use of this material is permitted. Permission from IEEE must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works
Tipologia: Postprint (accepted version)
Licenza: Accesso libero
Dimensione 995.49 kB
Formato Adobe PDF
995.49 kB Adobe PDF Visualizza/Apri
Artificial_Pancreas_In_Silico_Study_Shows_2021.pdf

solo utenti autorizzati

Licenza: Accesso privato - non pubblico
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3454721
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 12
social impact